The sclx stock price forecast factors in global biotech sentiment shifts, where investor confidence is rebounding due to innovation-driven progress and reduced regulatory delays. With the business potentially at an important milestone, we thought we'd take a closer look at Scilex Holding Company's ( NASDAQ:SCLX ) future prospects. Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The US$43m market-cap company’s loss lessened since it announced a US$167m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$88m, as it approaches breakeven. As path to profitability is the topic on Scilex Holding's investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable. NASDAQ SCLX traded down $3.14 during mid-day trading on Tuesday, hitting $22.56. The company's stock had a trading volume of 260,484 shares, compared to its average volume of 194,509. Scilex Holding Company has a 52-week low of $3.60 and a 52-week high of $39.90. The stock's fifty day simple moving average is $15.96 and its two-hundred day simple moving average is $9.94. The firm has a market capitalization of $157.02 million, a P/E ratio of -0.78 and a beta of 1.34. Technical and fundamental alignment makes the sclx stock price forecast relevant to both day traders and long-term investors. The convergence of moving averages often acts as a trigger for larger moves.